Our platform technologies were originally developed by United Biomedical and has a history of firsts. UBI developed the first peptide based diagnostic test, the first fully synthetic peptide vaccine against an infectious disease, and the first fully synthetic peptide vaccine against an endogenous host protein. In total, there have been over 3 billion doses of products sold based on these platform technologies.
Our new class of endobody vaccines are based on a series of technologies, the cornerstone of which is the UBITh immunogen. Unlike traditional vaccines that use KLH or toxoid carrier where the vast majority of response is directed at the toxoid, UBITh immunogens are virtually immunosilent. Thus, the vast majority of response is directed at the target B-cell epitope. The result is a highly targeted, specific, and immunogenic vaccine approach.
Whereas traditional vaccines will have difficultly overcoming the “self” barrier and generating titers against an endogenous host protein, our endobody vaccines are able to elicit high levels of targeted endobodies safely across a broad range of patients, both young and old and across ethnic diversities.
Our endobody vaccines also have a number of advantages over an antibody approach. Unlike antibodies which are externally produced and then passively infused into patients for the duration of treatment, endobody vaccines train the body to develop its own defense. The gradual induction of endobodies by the immune system is gentler on the body and the brain and thus, has an excellent safety profile. Also, rather than infuse monthly as with many antibodies, endobody vaccines may be administered bi-annually or even annually. Vaccines generally are more affordable, and have a history of being applied successfully both prophylactically and in combination, yielding greater potential impact on global health.